Body mass index (BMI) and waist-to-height ratio (a measurement of unhealthy waist size) represent important obesity treatment targets, associated with a lower risk of obesity-related complications A ...

Oral semaglutide improved glycemic parameters and cardiovascular risk factors for adults with overweight or obesity, with ...

The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent ...

The annual meeting of the American College of Gastroenterology was held from Oct. 24 to 29 in Phoenix, attracting participants from around the world, including gastroenterology and digestive disease ...

CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rivus Pharmaceuticals, Inc., a clinical-stage ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Addressing metabolic risk factors early with lifestyle change and GLP-1 therapy can reduce cardiovascular risks, says ...

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.